These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 10586637)

  • 1. Neuroendocrine studies and antidepressant drug development.
    Holsboer F
    Seishin Shinkeigaku Zasshi; 1999; 101(9):711-6. PubMed ID: 10586637
    [No Abstract]   [Full Text] [Related]  

  • 2. Central CRH system in depression and anxiety--evidence from clinical studies with CRH1 receptor antagonists.
    Holsboer F; Ising M
    Eur J Pharmacol; 2008 Apr; 583(2-3):350-7. PubMed ID: 18272149
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of serotonergic and noradrenergic systems in the pathophysiology of depression and anxiety disorders.
    Ressler KJ; Nemeroff CB
    Depress Anxiety; 2000; 12 Suppl 1():2-19. PubMed ID: 11098410
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Behavioral, neurochemical and neuroendocrine effects of the ethanolic extract from Curcuma longa L. in the mouse forced swimming test.
    Xia X; Cheng G; Pan Y; Xia ZH; Kong LD
    J Ethnopharmacol; 2007 Mar; 110(2):356-63. PubMed ID: 17134862
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuropeptides: relevance in treatment of depression and anxiety disorders.
    Madaan V; Wilson DR
    Drug News Perspect; 2009; 22(6):319-24. PubMed ID: 19771321
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Corticotropin-releasing factor, vasopressin and receptor systems in depression and anxiety.
    Keck ME
    Amino Acids; 2006 Oct; 31(3):241-50. PubMed ID: 16733617
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Corticotropin-releasing factor type-1 receptor antagonists: the next class of antidepressants?
    Nielsen DM
    Life Sci; 2006 Jan; 78(9):909-19. PubMed ID: 16122764
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New neuroendocrine aspects of depression and anxiety.
    Laakmann G; Hinz A; Neuhauser H
    Clin Neuropharmacol; 1986; 9 Suppl 4():245-7. PubMed ID: 3105879
    [No Abstract]   [Full Text] [Related]  

  • 9. The neurobiology of depression: inroads to treatment and new drug discovery.
    Nemeroff CB; Vale WW
    J Clin Psychiatry; 2005; 66 Suppl 7():5-13. PubMed ID: 16124836
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Getting closer to affective disorders: the role of CRH receptor systems.
    Müller MB; Wurst W
    Trends Mol Med; 2004 Aug; 10(8):409-15. PubMed ID: 15310462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug-dependent requirement of hippocampal neurogenesis in a model of depression and of antidepressant reversal.
    Surget A; Saxe M; Leman S; Ibarguen-Vargas Y; Chalon S; Griebel G; Hen R; Belzung C
    Biol Psychiatry; 2008 Aug; 64(4):293-301. PubMed ID: 18406399
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Pharmacological characterization and mechanisms of the novel antidepressive- and/or anxiolytic-like substances identified from Perillae Herba].
    Tsuji M; Miyagawa K; Takeuchi T; Takeda H
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2008 Aug; 28(4):159-67. PubMed ID: 18800619
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of corticotropin-releasing factor (CRF) in anxiety.
    Krysiak R; Obuchowicz E; Herman ZS
    Pol J Pharmacol; 2000; 52(1):15-25. PubMed ID: 10949116
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The neuroendocrinology of stress and the pathophysiology and therapy of depression and anxiety].
    Ströhle A
    Nervenarzt; 2003 Mar; 74(3):279-91; quiz 292. PubMed ID: 12627245
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stress responsive neurohormones in depression and anxiety.
    Ströhle A; Holsboer F
    Pharmacopsychiatry; 2003 Nov; 36 Suppl 3():S207-14. PubMed ID: 14677081
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The corticotropin-releasing factor receptor: a novel target for the treatment of depression and anxiety-related disorders.
    Grigoriadis DE
    Expert Opin Ther Targets; 2005 Aug; 9(4):651-84. PubMed ID: 16083336
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of CRF receptors in anxiety and depression: implications of the novel CRF1 agonist cortagine.
    Todorovic C; Jahn O; Tezval H; Hippel C; Spiess J
    Neurosci Biobehav Rev; 2005; 29(8):1323-33. PubMed ID: 16099044
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New directions in the development of antidepressants: the interface of neurobiology and psychiatry.
    Nemeroff CB
    Hum Psychopharmacol; 2002 Jun; 17 Suppl 1():S13-6. PubMed ID: 12404664
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Longitudinal neuroendocrine changes assessed by dexamethasone/CRH and growth hormone releasing hormone tests in psychotic depression.
    Owashi T; Otsubo T; Oshima A; Nakagome K; Higuchi T; Kamijima K
    Psychoneuroendocrinology; 2008 Feb; 33(2):152-61. PubMed ID: 18068306
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antidepressant-like activity of corticotropin-releasing factor type-1 receptor antagonists in mice.
    Nielsen DM; Carey GJ; Gold LH
    Eur J Pharmacol; 2004 Sep; 499(1-2):135-46. PubMed ID: 15363960
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.